Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JADE1 adjacent regulatory RNA (lncRNA-JADE)
- Target
- lncRNA-JADE
- Molecular classification
- Long non-coding RNA (lncRNA), Regulatory RNA, Other (not a protein, enzyme, receptor, or transporter; regulatory RNA acting mainly in epigenetic gene regulation)
01
Overview
JADE1 adjacent regulatory RNA, also known as lncRNA-JADE, is a highly conserved long non-coding RNA (~1.7 kb) transcribed adjacent to the JADE1 gene[1][4]. It is induced by DNA damage via the ATM/NF-κB axis and activates transcription of the neighboring JADE1 gene by recruiting the transcriptional co-activators BRCA1 and p300[1][3][4]. Physiologically, lncRNA-JADE supports cell proliferation and limits apoptosis, and is upregulated in breast cancer tissue compared to normal. Its transcriptional regulatory actions help coordinate chromatin acetylation and facilitate DNA damage recovery processes, making it biologically significant in cancer progression and potentially relevant for targeted therapeutic strategies[1][3][4].
- Other names
- lncRNA-JADEJADE1 adjacent regulatory RNAJADRR
02
Mechanism of action
Not directly drug-targetable, but acts by recruiting p300 and BRCA1 to the JADE1 promoter to promote transcription, influencing chromatin state and gene expression in the context of DNA damage response
03
Biological functions
Regulation of JADE1 gene transcriptionChromatin remodeling via recruitment of coactivator complexesDNA damage response (DDR), particularly ATM/NF-κB-dependent DNA damage signalingCell proliferation and apoptosis regulation; silencing leads to impaired proliferation and enhanced apoptosis, while overexpression has the opposite effect
04
Disease associations
Cancer (notably breast cancer, where it is upregulated and promotes tumorigenesis)Possible role in DNA repair deficiencies and related pathologies
05
Safety considerations
As a regulatory non-coding RNA, direct targeting presents challenges in specificity, off-target effects, and delivery for therapeutic modulation
06
Biomarkers
High lncRNA-JADE expression can serve as a biomarker for certain breast cancers and may correlate with proliferation indices and apoptosis resistance
Beyond the preview
Go deeper on JADE1 adjacent regulatory RNA (lncRNA-JADE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JADE1 adjacent regulatory RNA (lncRNA-JADE).